Long-term Impact of Infection With Novel Coronavirus (COVID-19)

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT04362150
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Study Details

LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data. LIINC specimens will be used to examine multiple questions involving the virologic, immunologic, and host factors involved in COVID-19, with a focus on understanding variability in the long-term immune response between individuals.

Key Dates

Start date
Apr 21, 2020
Status verified
Jun 2025
Primary completion
Dec 31, 2030
Completion
Dec 31, 2030

Study Design

Enrollment
800 participants (estimated)

Arms

  • Arm: COVID-19 positive, recovered
    Individuals with positive test for COVID-19 who have recovered from acute infection (21 days after symptom onset + improvement in symptoms + resolution of fever for 72 hours without fever reducing medicines).

Primary Outcome Measure

Participant age [ Time Frame: Baseline visit ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Zuckerberg San Francisco General Hospital (ZSFG)San FranciscoCalifornia94110
Michael J Peluso, MD
[email protected]
415-476-4082 x 119
Rebecca Hoh
[email protected]
415-476-4082 x 135
Steven G Deeks, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
Zuckerberg San Francisco General Hospital (ZSFG)· San Francisco, CA

Related Studies